This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Summary
- The company cannot recommend any practices, procedures or usage that deviate from the approved labeling.
- Please refer to the local labeling for relevant information regarding effect of ICOTYDE (icotrokinra) on fertility.
- The effect of icotrokinra on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.1
Animal Data
- In male rats, icotrokinra had no effects on mating, fertility, or early embryonic development of their offspring at oral doses up to 20 mg/kg/day (114 times the maximum recommended human dose [MRHD] based on area under the curve [AUC] comparison).1
- In female rats, icotrokinra had no effects on estrous cyclicity, mating, fertility, or early embryonic parameters at oral doses up to 70 mg/kg/day (335 times the MRHD based on AUC comparison).1
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 16 March 2026.
| 1 | Data on File. Icotrokinra. Company Core Data Sheet v001. Janssen Research & Development, LLC. EDMS-RIM-1387700; 2025. |